Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors by Palma, C et al.
Substance P (SP), an undecapeptide of the tachykinin family of
peptides, is the preferential endogenous ligand for the tachykinin
NK1 receptor (NK1R) (Maggi et al, 1993; Otsuka and Toshioka,
1993).
SP activates phospholipase C and stimulates the release of inter-
leukin 6 (IL-6) and prostaglandin E2 from human fetal astrocytes
in culture (Palma et al, 1997), indicating an involvement of this
neuropeptide in modulating astrocyte functions. Although there is
little evidence for the expression of tachykinin NK1R by astrocytes
in the normal adult brain (Maggi, 1997 for review), there is
evidence for up-regulation of this receptor by reactive astrocytes:
proliferating glial cells express high concentrations of NK1Rs after
transection of the optic nerve (Mantyh et al, 1989). Moreover, SP-
immunoreactive astrocytes were observed in multiple sclerosis
plaques (Kostyk et al, 1989) and in the forebrains of human infants
(Michel et al, 1986). Interestingly, high expression of SP receptors
(Henning et al, 1995), as well as the presence of the SP itself,
(Allen et al, 1985) has been described in human malignant gliomas
such as astrocytomas and glioblastomas. These observations
suggest a possible role of tachykinin NK1Rs in supporting the
development and growth of human astrocytomas.
The human astrocytoma cell line U373 MG expresses high
levels of tachykinin NK1R (Heuillet et al, 1993), and responds to
applied SP by releasing taurine (Lee et al, 1992) and a panel of
cytokines including IL-6, IL-8, leukaemia inhibitor factor (LIF)
and granulocyte–macrophage colony-stimulating factor (GM-
CSF) (Gitter et al, 1994; Palma et al, 1994, 1995; Palma and
Manzini, 1998). The release of cytokines by malignant glioma
cells has been associated with glioma progression (Gillespie,
1996); for example, IL-6 has been detected in tumour cysts and
cerebrospinal fluids in patients harbouring malignant gliomas
(Weller et al, 1991; Frei et al, 1992).
In addition to modulating cytokine production, SP induces
DNA synthesis and activates the mitogen-activated protein (MAP)
kinase pathway in U373 MG cells (Luo et al, 1996). However, the
actual ability of this neuropeptide to produce proliferation of
human glioma cells has not been determined until now.
In this study, we have further investigated the possible role of
the tachykinin NK1R in modulating growth/development of
human astrocytomas by addressing: (a) the expression of high-
affinity tachykinin NK1R in different human glioma cell lines; (b)
the presence/absence of functional responses (IL-6 secretion,
DNA synthesis) to applied tachykinins in glioma cells lines posi-
tive or negative for expression of the tachykinin NK1R (NK1R+
and NK1R– respectively); (c) the ability of SP to induce not only
DNA synthesis but also actual proliferation of human glioma cells;
(d) whether applied tachykinins induce the secretion of immuno-
suppressive cytokines (IL-10 and TGF-b1) from human gliomas;
(e) the possibility that neurokinin A (NKA), which is often co-
expressed with SP in the central nervous system, may affect
glioma cells in the same way as SP does; and (f) the effect of a
potent and selective antagonist for tachykinin NK1R on the
responses of human glioma cells to SP.
MATERIALS AND METHODS
Cell culture and media
Human glioma cell lines, U373 MG (astrocytoma grade III),
SNB-19 (malignant glioblastoma), DBTRG-05 MG (glioblastoma
multiforme), U138 MG (glioblastoma) were obtained from the
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American Type Culture Collection (Rockville, MD, USA); MOG-
G-CCM (anaplastic astrocytoma) were purchased from ECACC
(Salisbury, Wiltshire, UK). Cells were maintained in the appro-
priate media [U373 MG in RPMI-1640; SNB-19 in Ham’s F10;
U138 MG in Eagle’s modified Eagle medium (MEM) with 0.1 mM
non-essential amino acids, 1 mM sodium pyruvate and Earle’s
balanced salt solution (BSS); MOG-G-CCM in Ham’s F10/
Dulbecco’s modified Eagle medium (DMEM) (1:1); DBTRG-05
MG in RPMI-1640 with 10 mg ml–1 of adenine (Sigma, St Louis,
MO, USA), 1 mg ml–1 of adenosine triphosphate (Sigma),
100 mg ml–1 of L-cystine, 15 mg ml–1 of hypoxanthine, 50 mg ml–1
of L-isoleucine, 50 mg ml–1 L-proline, 100 mg ml–1 sodium pyru-
vate and 1 mg ml–1 of thymidine] containing 10% heat-inactivated
(65°C, 30 min) fetal bovine serum (FBS) with 5 mM HEPES,
2m ML -glutamine, 100 U ml–1 of penicillin and 100 m ml–1 of
streptomycin. All reagents, except those otherwise indicated, were
purchased from Gibco, Grand Island, NY, USA.
Reagents
Substance P, septide and NKA were purchased from Calbiochem-
Novabiochem, Laufelingen, Switzerland; lipopolysaccharide
(LPS) from Escherichia coli 0111:B4 were obtained from Sigma;
human recombinant IL-1b (specific activity 1.3´107 U mg–1) was
purchased from Janssen Biochimica, Beerse, Belgium. The
compound MEN 11467 [indolyl-3-carboxy-cis g2 Ac6c-D-2-Nal-
NMe-CO-CH2(4-CH3)phenyl] was synthesized in the Department
of Chemistry of Menarini Ricerche, Pomezia, Italy. MEN 11467 is
a potent, selective and specific ligand of human tachykinin NK1R.
In binding studies, MEN 11467 showed high affinity for NK1Rs
expressed in human cell lines (Ki = 0.4 ± 0.1 and Ki = 1.34 ± 0.32
for IM-9 and U373 MG respectively) and virtually no affinity
(Ki ³ 10 000 nM) for the NK1R present in rat urinary bladder
membranes, a result more than 1000-fold selective for the human
compared with the murine receptors. In addition, MEN 11467
has negligible effects on the binding of [125I]NKA to hamster
urinary bladder membranes (NK2 receptor) or of [3H]senktide
to guinea pig cerebral cortex membranes (NK3 receptor) (Cirillo
et al, 1998).
Binding assays
Binding assays were conducted on confluent intact cells in 24-well
plastic culture dishes, as described previously (Goso et al, 1994)
with minor modifications. Briefly, cells were rinsed and 500 ml of
RPMI-1640 supplemented with 0.2% glucose and 1% bovine
serum albumin was added to each well for 30 min. The buffer
was then aspirated and fresh buffer containing [3H]SP (specific
activity 40 Ci mmol–1; Amersham, Buckinghamshire, UK) or
[3H][Sar9,Met(O2)11]SP (specific activity 40.6 Ci mmol–1; New
England Nuclear, Du Pont de Nemours, NEN Division, Dreiech,
Germany) was added in a final volume of 500 ml. The non-specific
binding was defined as that displaceable by unlabelled 10 mM SP
or [Sar9,Met(O2)11]SP. The plates were incubated for 2 h at 4°C.
The reaction was stopped by aspirating the medium and then
rinsing each well three times with 1 ml of 0.9% sodium chloride in
10 mM HEPES (pH 7.2) wash buffer. The cells were solubilized in
5% sodium dodecyl sulphate in 0.01 M hydrochloride acid (0.5 ml)
at 37°C for 1 h and radioactivity was quantified in a liquid scintil-
lation spectrometer.
For saturation binding experiments, cells were incubated
with increasing concentrations of [3H]SP (0.1–5 nM) or
[3H][Sar9,Met(O2)11]SP (0.1–5 nM). For competition binding
experiments, cells were incubated with 2 nM of both radioligands,
in the presence of varying amounts of competitor. Binding data
were analysed using the iterative curve fitting program, Ligand
(Munson and Rodbard, 1980).
DNA synthesis
Human glioma cells were plated on 24-well tissue culture plates
(2´104 cells per well in 1 ml of medium, unless otherwise noted)
in their appropriate media with low concentration or without FBS
as indicated throughout the text. The stimulants were then added
and left in the culture media for the entire length of the experi-
ment. [3H]methyl-thymidine [specific activity 82.5 Ci mmol–1,
NEN-Du Pont De Nemours Italiana, Cologno Monzese (MI),
Italy] at a concentration of 1 mCi ml–1 was added to each cell
culture for the last 24 h of incubation. At the end of each experi-
mental point, the cells were treated with 1 ml of 5% cold
trichloroacetic acid (TCA) for 10 min at 4°C. The acid was
removed, and the cells were washed with double-distilled water
(three times, 2 ml each time). The cells were removed from each
well with 0.5 ml of 0.1 N sodium hydroxide and incubated for
15 min. Each sample was then neutralized with 0.1 N hydrochloric
acid and the radioactivity was quantified in a liquid scintillation
spectrometer.
Proliferation studies
Human glioma cells were plated on 24-well tissue culture plates
(2´104 cells per well in 1 ml of medium, unless otherwise noted)
Table 1 Inhibitory effect of the tachykinin NK1 receptor antagonist MEN 11467 on SP and NKA-induced mitogenic effect on human glioma cell lines
Conditions SNB-19 DBTRG-05 MG U373 MG
Mediuma 58 000 ± 4999b 27 147 ± 2936 55 333 ± 8671
MEN 11467 (100 nM) 60 000 ± 3945 28 586 ± 3789 58 000 ± 4999
SP (100 nM) 90 333 ± 5696** 44 560 ± 3267* 102 666 ± 8346**
SP (100 nM) + MEN 11467 (100 nM) 60 666 ± 4055 29 706 ± 3336 61 666 ± 4055
NKA (100 nM) 97 333 ± 3179** n.t. 111 333 ± 8830**
NKA (100 nM) + MEN 11467 (100 nM) 62 666 ± 4115 n.t. 60 666 ± 7115
aHuman glioma cell lines, SNB-19, DBTRG-05 MG and U373 MG, were plated at 20 000 cells per well in appropriate medium containing 0.5%, 0.2% and 0.8%
FBS respectively. Tachykinins and MEN 11467 were then added to the culture. After 72 h of incubation for DBTRG-05 MG and SNB-19 and 96 h for U373 MG,
the cell numbers in the well were counted. bMean of cell numbers ± s.e.m. of a triplicate. *P < 0.05 Anova one-way and Tukey test vs medium. **P < 0.01 Anova
one-way and Tukey test vs medium. n.t., not tested.238 C Palma et al
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in their appropriate media in serum-free conditions or with low-
concentration FBS as indicated. The stimulants were then added
and left in the culture medium for the entire experiment length. At
the end of each experimental point, the medium was aspirated and
the living cells detached with 200ml of trypsin. The cells were
then diluted in the vital colorant trypan blue (1:1) and counted in
haemocytometer counting chambers (Newbauer and Nageotte).
Detection of IL-6, IL-10 and TGF-b1 in supernatants of
human glioma cell lines
Glioma cells were detached by trypsinization, washed in serum-
free RPMI-1640, seeded in their appropriate FBS medium at
3.5´105 cell per well in 24-well culture plates, and allowed to
adhere for 24h at 37°C. Then the cultured medium was removed,
the cells were washed three times in serum-free RPMI-1640, and
fresh media containing low (1%) or high (10%) FBS were added.
Cells were cultured for 18h, unless otherwise indicated, in the
presence or absence of SP, NKA, IL-1b. When necessary, the NK1
receptor antagonists were co-administered with the stimulants. In
all experimental conditions, cell viability was always greater than
99%, as determined by the Trypan Blue exclusion method. After
the incubation time, the supernatants were collected and spun free
of cells and debris. IL-6, IL-10 and TGF-b1 levels were assayed
by specific ELISA kits (Quantikine, Research and Diagnostic
System, Minneapolis, MN, USA or Biotrak, Amersham). To acti-
vate latent TGF-b1 to the immunoreactive form, 0.5ml of cell
culture supernatants were incubated for 10min at room tempera-
ture with 0.1ml 1Nhydrochloric acid. The acidified samples were
then neutralized by adding 0.1ml 1.2Nsodium hydroxide/0.5M
HEPES before being assayed. Significant levels of latent TGF-b1
were found in FBS, whereas no IL-6 or IL-10 was detected in FBS
media even when FBS was present at 10%.
The data were analysed using linear regression of the
Microplate Manager Program (Bio-Rad Laboratories, Richmond,
CA, USA), and simultaneous fitting of families of sigmoidal dose-
response curves using the four-parameter logistic equation with
statistical analysis and elaboration of IC50 and EC50 values was
performed using the program Allfit version 1.05 (De Lean et al,
1978).
Statistical analysis
All data in the text and figures are means± s.e.m. Statistical
analysis of data was performed with Anova one-way and Tukey
tests.
RESULTS
Identification and characterization of SP binding sites
(NK1R) on human glioma cell lines
By studying the specific binding of [3H]SP, evidence for expres-
sion of tachykinin NK1R was obtained for SNB-19 and DBTRG-
05MG cell lines in addition to U373MG cells. In these cell lines,
the specific binding of [3H]SP was usually >80% of total binding,
as defined in the presence of 10mMunlabelled SP. The binding of
[3H]SP was saturable and Scatchard analysis indicated a single
population of high-affinity binding sites: the Kd and Bmax values
obtained in the three cell lines are reported in Figure 1 along with
the corresponding Scatchard plots.
Because the presence of tachykinin NK1R in SNB-19 and
DBTRG-05MG cell lines was not studied previously, saturation
binding assays with the synthetic NK1R selective ligand
[3H][Sar9,Met(O2)11]SP were also performed in these cell lines.
Scatchard analysis showed again a single population of high-
affinity binding sites (Kd of 0.12±0.04nM and Bmax of
22062± 3309 for SNB-19 cells; Kd of 0.08± 0.02nMand Bmax of
13664± 1370 for DBTRG-05MG cells).
Specific binding of [3H]SP or [3H][Sar9,Met(O2)11]SP was not
observed in U138MG and MOG-G-CCM cells, indicating that
these human glioma cell lines do not express typical NK1R.
0.2
0.15
0.1
0.05
0
10 20 30 40 8050 7060
Bound (pM)
B
o
u
n
d
/
f
r
e
e
U373 MG
Kd=0.17±0.007 nM
Bmax=56 333±6157 binding sites per cell
0.14
0.12
0.1
0.08
0
0 203040
Bound (pM)
B
o
u
n
d
/
f
r
e
e
SNB-19
Kd=0.13±0.01 nM
Bmax=18 252±2522 binding sites per cell
10 50
0.06
0.04
0.02
0.08
0.1
5 203040
Bound (pM)
B
o
u
n
d
/
f
r
e
e
DBTRG-05 MG
Kd=0.12±0.02 nM
Bmax=15 119±1469 binding sites per cell
10
0.5
0.4
0.2
15 25 35 45
0.7
0.6
0.3
Figure 1Scatchard analysis of specific [3H]SP binding to human glioma cell
lines. Data for Scatchard plots are from one experiment representative of
three run in triplicate, whereas the indicated Kd and Bmax values are from the
simultaneous analysis with Ligand program of the three independent
experimentsTachykinin NK1 receptors in glioma activation and growth 239
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SP and NKA stimulate the release of IL-6 from NK1R+
glioma cell lines
SNB-19 and U373 MG glioma cell lines are able to spontaneously
release IL-6, not only in medium containing high-concentration
FBS (10%) (Gitter et al, 1994; Palma et al, 1994, 1995; Palma and
Manzini, 1998) but also when cultured in low-concentration FBS
(1%) (Figure 2). Even in the more stringent culture conditions, SP
and NKA induced a concentration-dependent release of IL-6. The
EC50 values were 2 ± 0.4 and 3.8 ± 0.5 nM for SP in SNB-19 and
U373 MG glioma cells, respectively; the corresponding EC50
values for NKA were about tenfold higher than for SP (37 ± 9 and
26 ± 7n M for U373 MG and SNB-19 cells, respectively).
DBTRG-05 MG cells, which do not spontaneously secrete IL-6,
did not respond with augmented IL-6 secretion in response to
added SP (n = 3). However, if challenged with IL-1b (100 U ml–1),
a secretion of IL-6 was established (686 ± 20 pg ml–1) from
DBTRG-05 MG cells; in these conditions, SP produced a
concentration-dependent potentiation of the response to IL-1b
(739 ± 2, 893 ± 22, 1105 ± 26 and 1186 ± 15 pg ml–1 at 1, 10, 100
and 1000 nM of SP, respectively).
The involvement of the tachykinin NK1R in the stimulant action
of SP on basal or stimulated (in DBTRG-05 MG cells) secretion of
IL-6 was confirmed by studying the inhibitory action of the potent
and selective tachykinin NK1R antagonist MEN 11467 (Figure 3).
MEN 11467 produced a concentration-dependent and comparable
inhibition of the responses to SP in the three NK1R+glioma cell lines
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Figure 2 Release of IL-6 induced by SP and NKA in human glioma cell
lines. U373 MG and SNB-19 cells were cultured for 18 h in FBS 1% medium
in the presence of SP or NKA at the indicated concentrations before
collection of supernatants for IL-6 measurement with a specific ELISA kit. The
data are presented as means±s.d. of triplicate determinations after
subtraction of spontaneous IL-6 secretion (250±15 and 900±13 pg ml–1 for
U373 MG and SNB-19 cells respectively) of one representative experiment
Figure 3 Inhibition of SP-induced IL-6 release in human glioma cell lines by
the tachykinin NK1 receptor antagonist MEN 11467. U373 MG, SNB-19 and
DBTRG-05 MG cells, cultured in FBS 1% medium, were treated with SP
(100 nM) (in combination with IL-1b 100 U ml–1 for DBTRG 05 MG cells) in the
absence or presence of increasing concentrations of MEN 11467 for 18 h.
IL-6 protein levels were determined in culture supernatants by specific
ELISA. The data are presented as per cent of inhibition vs the amount of IL-6
released in absence of MEN 11467; the data are the means±s.e.m. of four
independent experiments for U373 MG cells and the means±s.e.m. of
triplicate determinations of one representative experiment for SNB-19 and
DBTRG-05 MG cells
Figure 4 Release of TGF-b1 induced by SP in U373 MG cells. U373 MG
were treated with increasing concentration of SP (A) or with SP (100 nM) in
the absence or presence of MEN 11467 (100 nM) (B) for 18 h. TGF-b1
protein levels were determined in culture supernatants, previous activation of
the latent form, by specific ELISA. Values are means±s.e.m. of three
independent experiments run in duplicate (A) or means±s.e.m. of triplicate
determinations of one representative experiment (B). *P < 0.01 Anova one-
way and Tukey test vs the condition in absence of MEN 11467240 C Palma et al
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with IC50 values of 0.8 ± 0.1, 0.6 ± 0.2 and 0.6 ± 0.3 nM for U373
MG, SNB-19 and DBTRG-05 MG cells, respectively (Figure 3).
On its own, MEN 11467 neither significantly affected the basal
secretion of IL-6 from SNB-19 and U373 MG cell lines (486 ± 26
and 420 ± 49 pg ml–1; 900 ± 16 and 843 ± 5 pg ml–1 in the absence
or presence of 100 nM MEN 11467 for SNB-19 and U373 MG
cells respectively), nor the IL-6 secretion induced by IL-1b from
DBTRG-05 MG cells (690 ± 17 pg ml–1 and 604 ± 11 pg ml–1 in
the absence or presence of 100 nM MEN 11467, respectively).
To confirm the specificity of the stimulatory effects of SP, the
effect of this peptide was also investigated in NK1R– glioma cell
lines; up to 100 nM, SP neither induced IL-6 secretion nor affected
IL-1b-stimulated IL-6 release from U138 MG or MOG-G-CCM
cells (data not shown, n = 2 for each cell line).
SP stimulates the production of TGF-b1 but not IL-10
from U373 MG cells
The possible secretion of immunodepressant cytokines, IL-10 and
TGF-b1, was investigated in U373 MG cells. No spontaneous
secretion of IL-10 was measured nor any secretory response was
observed upon challenge with IL-1b (100 U ml–1), LPS (1–
20 ng ml–1) and SP (1–1000 nM) for 24–72 h in the presence of
low- (1%) or high-concentration (10%) FBS (n = 3).
In contrast, a spontaneous release of the inactive form of TGF-
b1 was detected (1033 ± 92 pg ml–1) after 24 h of culture in the
Figure 5 SP effects on U373 MG cellular growth. U373 MG cells (20 000
cells per well) were stimulated in serum-free medium with SP (10 or 100 nM),
and at the indicated time points the number of cells in the well were counted
by haemocytometer counting chamber (A) or [3H]methyl-thymidine
incorporation into DNA was measured (B). [3H]methyl-thymidine was added
to the cell culture for the last 24 h of incubation. Data are presented as
means±s.e.m. of triplicate determination of one representative experiment.
*P < 0.05 Anova one-way and Tukey test vs medium. **P < 0.01 Anova
one-way and Tukey test vs medium
Figure 6 Tachykinin effects on U373 MG cellular growth in the presence of
serum. U373 MG cells (20 000 cells per well) were stimulated in medium
containing FBS at 0.8% with SP or NKA (100 nM). At the indicated time
points, the number of cells in the well were counted by haemocytometer
counting chamber. Data are presented as means±s.e.m. of triplicate
determination of one representative experiment. *P < 0.05 Anova one-way
and Tukey test vs medium. **P < 0.01 Anova one-way and Tukey test vs
medium
Figure 7 SP effects on SNB-19 and DBTRG-05 MG cellular growth. SNB-
19 cells (A) (20 000 cells per well) in serum-free medium or DBTRG-05 MG
cells (B) (20 000 cells per well) in medium containing FBS at 0.2% were
stimulated with SP (10 or 100 nM). At the indicated time points, the number of
cells in the well were counted by haemocytometer counting chamber. Data
are presented as means±s.e.m. of triplicate determination of one
representative experiment. *P < 0.05 Anova one-way and Tukey test vs
medium. **P < 0.01 Anova one-way and Tukey test vs medium
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presence of low-concentration FBS (1%). SP potentiated, in a
concentration-dependent manner, the secretion of the inactive
form of TGF-b1 (Figure 4A). This response involves the
activation of tachykinin NK1R because MEN 11467 (100nM)
completely blocked the SP (100nM)-stimulated release of TGF-b1
(Figure 4B). However, the presence of active TGF-b1 molecules
was never observed in the supernatants of SP-triggered U373MG
cells. TGF-b1 release was not modulated by stimulation with LPS
(20ng ml–1) or IL-1b(100U ml–1).
SP induces DNA synthesis and proliferation in NK1R+
glioma cell lines
The aim of these experiments was to verify the ability of SP to
stimulate growth of human glioma cell lines by measuring both
DNA synthesis (assessed by evaluating thymidine uptake) and cell
proliferation (by counting the number of cells at different times
from exposure to SP).
In a first series of experiments (Figure 5), U373MG cells were
plated at low concentration (2´104 cells per well in 24-well tissue
culture plates) in serum-free medium, and time course experi-
ments were performed in the presence of SP. No significant
increase in the number of cells was observed in control conditions
(Figure 5); SP (10–100nM) increased DNA synthesis already after
24h of stimulation, whereas the number of cells present in the
wells at this time was similar for treated and untreated samples.
However, the addition of SP determined a doubling of cell number
after 48h of culture (Figure 5).
In another series of experiments (Figure 6), the ability of SP to
stimulate the growth of U373MG cells was determined in the pres-
ence of low-concentration serum (0.8%), which stimulates cell
growth to some extent; as shown in Figure 6, a stimulant action of SP
on cell number above the spontaneous growth was observed since 96
h from addition of the neuropeptide and a stimulant effect was
evident up to 192h (Figure 6). In these conditions, the mitogenic
effect of SP was not concentration-dependent (1–1000nM); the
proliferative response observed at 1nMwas similar to that obtained
at the highest concentration (55333±8671, 94000±11222 and
102000± 6060 cells per well after 96h of incubation in medium
alone, SP 1nMand SP 1000nM, respectively).
A third series of experiments showed (Figure 7) that application
of SP determines a mitogenic effect on other NK1R+ human glioma
cell lines, SNB-19 and DBTRG-05MG cell lines. In contrast, the
NK1R– cell lines U138MG and MOG-G-CCM did not show any
increase in DNA synthesis (after 48h of stimulation, data not
shown, n= 2 for each cell line) or proliferation after challenge
with SP (55000±4582 and 61666±7023 cells per well;
81000±11357 and 77000± 4582 cells per well after 96h of
incubation in absence or in the presence of 100nMSP for U138
MG and MOG-G-CCM, respectively).
An NK1R antagonist inhibits SP-induced growth in
glioma cell lines
The tachykinin NK1R antagonist MEN 11467 (100nM)
completely reverted the SP-induced thymidine uptake by U373
MG cells, whereas that induced by IL-1b(10 and 40U ml–1) was
not significantly reduced (Figure 8). Moreover, the enhanced
proliferation of NK1R+ glioma cell lines induced by SP was inhib-
ited by MEN 11467 (Table 1).
NKA stimulates glioma cell growth via tachykinin
NK1Rs
Like SP (Figure 5), NKA increased the thymidine uptake in U373
MG cells (38476± 870, 56855± 2794 and 71827± 3949 d.p.m.,
after 24h culture in serum-free medium, NKA 10nM and NKA
100nM, respectively). Moreover, in experiments performed in
media containing low-concentration serum (0.8%), NKA (100nM)
stimulated the proliferation of SNB-19 cell and U373MG cell
lines (Figure 7 and Table 1). The mitogenic effect of NKA was
completely blocked by MEN 11467 (Table 1).
DISCUSSION
The present findings expand previous observations (Luo et al, 1996;
Sharif et al, 1996) on the role played by tachykinins (via NK1R) in
producing biological responses which are potentially relevant for
the development and growth of human gliomas. In particular, the
present study provides the following novel observations: (a) in addi-
tion to U373MG cells, two glioma cell lines have been character-
ized as being NK1R+ (SNB-19 and DBTRG-05MG), whereas two
other cell lines were found to be NK1R– (MOG-G-CCM and U138
MG); (b) the demonstration of the mitogenic properties of SP in
terms not only of DNA synthesis but also as an actual increase in
glioma cell number; (c) a positive correlation has been established
between functional responses (modulation of IL-6 secretion and
proliferation) of human glioma cell lines and the expression of
NK1R; (d) in keeping with the above, the activation of human
glioma cell lines by tachykinins was blocked by the highly potent
and selective tachykinin NK1R antagonist MEN 11467; (e) in addi-
tion to SP, NKA also stimulates cytokine secretion and enhances
proliferation in human glioma cell lines via the NK1R; (f) stimula-
tion of the NK1R also determines the release of the immunosuppres-
sant cytokine TGF-b1 from the U373MG cell line.
Application of SP or of tachykinin NK1R selective agonists
determines a number of functional responses in U373MG glioma
cells: the stimulation of phosphatidyl inositol (Pi) turnover,
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Figure 8Inhibition of SP-induced DNA synthesis in U373MG cells by the
tachykinin NK1 receptor antagonist MEN 11467. U373MG cells (20000 cells
per well) were stimulated in serum-free medium containing 1mCi ml–1 of
[3H]methyl-thymidine with SP (40nM) or IL-1b(10 or 40U ml–1) in the
absence or presence of MEN 11467 (100nM) for 24h. TCA-precipitable
material was quantified by liquid scintillation counting and plotted as
[3H]methyl-thymidine incorporation. Data are presented as means±s.e.m. of
triplicate determination of one representative experiments. *P < 0.01 Anova
one-way and Tukey test vs the condition in absence of MEN 11467242 C Palma et al
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mobilization of intracellular calcium, release of taurine, activation
of MAP kinase and secretion of cytokines (Eistetter et al, 1992;
Lee et al, 1992; Gitter et al, 1994; Palma et al, 1994, 1995; Luo et
al, 1996; Palma and Manzini, 1998). Therefore, the activation of
NK1R initiates a set of cellular responses which eventually
includes stimulation of DNA synthesis, cell division and prolifera-
tion. The actual proliferation of human glioma cells detected in
this study occurs both in serum-free conditions and in the presence
of serum; the latter observation (Figure 6) indicates that SP can co-
operate with other growth factors in regulating the proliferation of
NK1R+ cells. In contrast, the former observation indicates that SP
is in itself a sufficient stimulus for promoting glioma cell prolifer-
ation. Even in the most stringent serum-free conditions, an actual
proliferative response to SP was evident only at > 24 h from its
applications; therefore, the question arises as to whether the
continuous occupancy of NK1R during this time lag is required for
the triggering of the proliferative response, or, as an alternative,
whether the initial stimulus provided by SP determines glioma cell
proliferations indirectly through the release of other factors (e.g.
IL-6, see below). As a matter of fact, SP application induces a
lasting expression of kB-dependent genes (Lieb et al, 1998), such
as expression of mRNA coding for the mitogenic cytokine IL-6
(Palma and Manzini, 1998). It appears, therefore, conceivable that
the actual proliferation of glioma cells, as detected in this study,
had involved some intermediate step in the sequence of events
initiated by the occupancy of tachykinin NK1R. The secretion
of cytokines such as IL-6 or TGF-b1 could provide an autocrine
/paracrine loop for glioma progression. In fact, both IL-6 and
TGF-b1 roles facilitate glioma cell proliferation (Jennings et al,
1991; Munoz-Fernandes and Fresno, 1993).
At the present time, we cannot totally exclude that, in addition
to its role as growth promoter, SP may also have enhanced glioma
cell survival and plating efficiency. However, the initial number of
cells present in the wells was similar in the presence or absence of
SP, suggesting that a putative effect of this neuropeptide on plating
efficiency, if any, was a minor one. In contrast, further studies
should be performed to clarify whether SP can increase the
number of cells entering the cell cycle and/or induce an improved
survival by preventing apoptosis, which is a common event in
tumour cells lacking in growth factors.
The present findings demonstrate that, in addition to SP, NKA
also stimulates the growth of human glioma cells via the NK1R.
This observation is of particular interest because SP and NKA can
be produced through the expression of the same gene in the CNS
and are frequently co-localized and co-released by the same
neurons (Maggi et al, 1993; Otsuka and Yoshioka, 1993 for
reviews). NKA is the natural ligand with preferential affinity for
tachykinin NK2 receptors, but it can also act as a full agonist at
NK1Rs (Maggi and Schwartz, 1997 for review). Indeed, because
NK2 receptors are poorly expressed, if not absent, in the
mammalian CNS (Otsuka and Yoshioka, 1993), it is currently
believed that SP and NKA act in concert by stimulating NK1R at
most mammalian CNS synapses.
Sharif et al (1996) reported that activation of the MAP kinase
pathway and [3H]thymidine incorporation into DNA were induced
by NKA as efficiently as SP when fixed high equimolar concentra-
tions of tachykinin were used (100 nM and 1 mM respectively). In
our hands, NKA induced responses (secretion of IL-6, stimulation
of DNA synthesis and cell proliferation) which were quantitatively
comparable to those produced by SP. However, our data document
that NKA has about a ten fold lower potency in stimulating IL-6
secretion from NK1R+ human glioma cell lines than SP, in accor-
dance with the lower affinity of NKA for NK1Rs, as shown in
competition binding vs [3H]SP in U373 MG cells (Heuillet et al,
1993) and in SNB-19 cells (our unpublished observation). Our
findings provide unequivocal evidence that the actions of NKA on
human gliomas are mediated via NK1R stimulation. In fact NKA
was active in NK1R+ but not in NK1R– cell lines, and its effects in
NK1R+ glioma cells were blocked by MEN 11467.
We also demonstrated that SP, via NK1R occupancy, stimulates
the secretion of the immunodepressant cytokine TGF-b1. This
finding is of particular interest because it provides an additional
mechanism through which tachykinins may facilitate the growth
and development of human gliomas. TGF-b1 and IL-6 contribute
to the general immunodepression observed in glioma patients
(Roszman et al, 1991; Ausiello et al, 1991). IL-6 inhibits the secre-
tion of IL-1b and TNF-a and can counteract the activation of the
immune system in this way (Schindler et al, 1990). TGF-b1
induces apoptosis of tumour-infiltrating lymphocytes, signifi-
cantly reducing their cytotoxic properties, and depresses the
activity of natural killer cells (Bodmer et al, 1989; Weller et al,
1995). Therefore, a stimulation by tachykinins of the local release
of immunosuppressant cytokines could play a facilitatory role in
the growth and development of gliomas by helping tumour cells to
evade attack by the immune system.
High-grade human malignant glioma are inevitably lethal
neoplasms, and the median survival of patients treated with stan-
dard cytoreductive surgery and post-operative radiotherapy is in
the range of 1 year. The task of developing additional or novel
treatments crucially requires an increase in knowledge of the phys-
iology and molecular biology of these brain tumours. We have
gathered evidence indicating that tachykinins (SP and NKA),
through a specific stimulation of NK1R, have functional effects on
several human glioma cell lines, resulting in proliferation, mitoge-
nesis and release of soluble factors which can influence the tumour
cell–host interactions including modulation of the immune system.
Altogether, these observations suggest a possible role of
tachykinins, via NK1Rs in glioma development and growth. It
should be noted that SP was found in human glioma tissues (Allen
et al, 1985), and human astrocytes themselves are a possible
source of tachykinins (Michel et al, 1986). In addition, an overex-
pression of NK1Rs seems to occur in gliomas in relation to their
degree of malignancy (Henning et al, 1995). Therefore, an
autocrine/paracrine loop providing a facilitatory input on tumour
growth could be devised to exist in the glioma itself. In addition,
the expression of NK1Rs in peritumoral and tumoral blood vessels
(Henning et al, 1995) suggests a role of SP in facilitating tumour
blood supply by virtue of its NK1R-mediated angiogenic and
vasodilator properties (Ziche et al, 1990). Tachykinins are multi-
faceted factors for amplification of the malignant growth of human
glioma cells. In view of the obligatory role of NK1Rs in all these
effects of tachykinins, the pharmacological blockade of NK1Rs
could represent a new strategy to slow down glioma tumour
growth in humans.
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